drugset / Trial / NCT07266558

A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)

NCT07266558

Phase 4 Active not recruiting 30000 enrolled ModernaTX, Inc.
RandomizedParallel-groupTriple-blindPrevention

Summary

The purpose of this study is to evaluate the efficacy and safety of mRNA-1283 and mRNA-1273 (variant formulations) in adults 50 to 64 years of age without high risk factors for severe COVID-19.

Timeline

Start
2025-11-26
Primary completion
2027-06-16
Completion
2027-06-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Elasomeran Messenger RNA (mRNA) Intramuscular
Subject mRNA-1283 Messenger RNA (mRNA) Intramuscular

Indications